

## **PENDING CLAIMS**

### **Clean Version of Pending Claims under 37 C.F.R. 1.121(c)(3)**

1. An isolated polypeptide consisting of the amino acid sequence as set forth in SEQ ID NO: 7.
6. A fusion polypeptide consisting of the polypeptide of Claim 1 fused to a heterologous amino acid sequence, wherein the heterologous sequence is not joined to the polypeptide of Claim 1 in nature.
7. The fusion polypeptide of Claim 6 wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof.
8. A composition comprising the polypeptide of Claim 1 and a pharmaceutically acceptable formulation agent.
9. The composition of Claim 8 wherein the pharmaceutically acceptable formulation agent is a carrier, adjuvant, solubilizer, stabilizer, or anti-oxidant.
11. The polypeptide of Claim 1 which is covalently modified with a water-soluble polymer.
12. The polypeptide of Claim 11 wherein the water-soluble polymer is selected from the group consisting of polyethylene glycol, monomethoxy-polyethylene glycol, dextran, cellulose, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols, and polyvinyl alcohol.
13. The polypeptide of Claim 11 wherein the water-soluble polymer is selected from the group consisting of polyethylene glycol and dextran.